American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between February 13 th and 15 th 2025, was host to the Panning for Gold: The Role of ctDNA as ...

Several cardiovascular risk factors, such as advanced age and smoking history, are prevalent among lung cancer patients at ...

CLINICAL complete response (cCR) is a strong predictor of prognosis in patients with unresectable hepatocellular carcinoma ...

New model predicts HCC risk in noncirrhotic chronic hepatitis B patients, improving early detection strategies.

The lack of NHS funded testing for this type of cancer in Scotland means patients are denied targeted treatments unless they ...

Unlike the other more well-known type of liver cancer, hepatocellular carcinoma ... As he was admitted to a liver ward for a ...

A VISION-like, Single-Center Analysis Predicting Outcomes of Indeterminate Bone Lesions on 18F-DCFPyL PSMA PET/CT Scans ... in prostate cancer 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new study. Researchers at Karolinska Institutet have investigated how immune cells ...

You might have an MRI scan or a CT scan if the biopsy shows you have cancer. The scan will show where the cancer is and how big it is. This helps your doctor decide which treatment you need.

A multicenter prospective study to evaluate the efficacy of resection for initially unresectable hepatocellular carcinoma after atezolizumab combined with bevacizumab (the RACB study): Short-term ...

A multicenter, phase 2 study of atezolizumab plus bevacizumab (atezo+bev) combination therapy in patients with unresectable hepatocellular carcinoma (HCC) and Child–Pugh class B cirrhosis: CHALLENGE ...